JP2021520232A5 - - Google Patents

Info

Publication number
JP2021520232A5
JP2021520232A5 JP2021504131A JP2021504131A JP2021520232A5 JP 2021520232 A5 JP2021520232 A5 JP 2021520232A5 JP 2021504131 A JP2021504131 A JP 2021504131A JP 2021504131 A JP2021504131 A JP 2021504131A JP 2021520232 A5 JP2021520232 A5 JP 2021520232A5
Authority
JP
Japan
Prior art keywords
sequence encoding
sequence
cells
item
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021504131A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021520232A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/026062 external-priority patent/WO2019195727A1/en
Publication of JP2021520232A publication Critical patent/JP2021520232A/ja
Publication of JP2021520232A5 publication Critical patent/JP2021520232A5/ja
Withdrawn legal-status Critical Current

Links

JP2021504131A 2018-04-05 2019-04-05 黄斑ジストロフィーを処置するための組成物及び方法 Withdrawn JP2021520232A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862653131P 2018-04-05 2018-04-05
US62/653,131 2018-04-05
PCT/US2019/026062 WO2019195727A1 (en) 2018-04-05 2019-04-05 Compositions and methods for treating macular dystrophy

Publications (2)

Publication Number Publication Date
JP2021520232A JP2021520232A (ja) 2021-08-19
JP2021520232A5 true JP2021520232A5 (enExample) 2022-04-12

Family

ID=66223872

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021504131A Withdrawn JP2021520232A (ja) 2018-04-05 2019-04-05 黄斑ジストロフィーを処置するための組成物及び方法

Country Status (21)

Country Link
US (2) US20190307900A1 (enExample)
EP (1) EP3775233A1 (enExample)
JP (1) JP2021520232A (enExample)
KR (1) KR20210005040A (enExample)
CN (1) CN113056561A (enExample)
AU (1) AU2019247864A1 (enExample)
BR (1) BR112020020204A2 (enExample)
CA (1) CA3096088A1 (enExample)
CL (1) CL2020002561A1 (enExample)
CO (1) CO2020013690A2 (enExample)
EA (1) EA202092069A1 (enExample)
IL (1) IL277779A (enExample)
JO (1) JOP20200253A1 (enExample)
MA (1) MA52199A (enExample)
MX (1) MX2020010477A (enExample)
PE (1) PE20210918A1 (enExample)
PH (1) PH12020551641A1 (enExample)
RU (1) RU2020132890A (enExample)
SG (1) SG11202009759SA (enExample)
TW (1) TW202003052A (enExample)
WO (1) WO2019195727A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020047476A1 (en) * 2018-08-31 2020-03-05 University Of Florida Research Foundation, Incorporated Adeno-associated viral vectors for the treatment of best disease
EP3870148A4 (en) 2018-10-25 2022-11-09 Takeda Pharmaceutical Company Limited AAV TRIPLE PLASMID SYSTEM
WO2020140007A1 (en) * 2018-12-28 2020-07-02 University Of Rochester Gene therapy for best1 dominant mutations
BR112022017182A2 (pt) * 2020-02-28 2022-11-08 Univ Pennsylvania Tratamento de bestrofinopatias autossômicas recessivas e métodos para avaliação das mesmas
CN111849998A (zh) * 2020-07-29 2020-10-30 武汉纽福斯生物科技有限公司 编码人卵黄状黄斑病蛋白1的核酸分子及其应用
WO2024064608A2 (en) * 2022-09-20 2024-03-28 Intergalactic Therapeutics, Inc. Best1 vectors and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009153563A1 (en) * 2008-06-18 2009-12-23 Oxford Biomedica (Uk) Limited Virus purification
US9163259B2 (en) * 2012-05-04 2015-10-20 Novartis Ag Viral vectors for the treatment of retinal dystrophy
CA2930282C (en) * 2013-11-20 2024-09-10 Universita Degli Studi Di Napoli Federico Ii Artificial DNA-Binding Proteins and Their Uses
KR102281881B1 (ko) * 2013-12-06 2021-07-27 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름) 대상체의 망막 색소 상피에서 목적 폴리뉴클레오티드를 발현시키기 위한 방법 및 약학적 조성물
GB201322798D0 (en) * 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
CA2979120A1 (en) * 2015-03-03 2016-09-09 Fondazione Telethon Multiple aav vector system for expressing genes over 5 kilobases, comprising at least one degradation signal and uses thereof
EP3374494A4 (en) * 2015-11-11 2019-05-01 Coda Biotherapeutics, Inc. CRISPR COMPOSITIONS AND METHODS OF USE THEREOF FOR GENE THERAPY

Similar Documents

Publication Publication Date Title
US12383587B2 (en) AAV triple-plasmid system
JP2022535749A5 (enExample)
US8129510B2 (en) Minigene expression cassette
JP2022508182A5 (enExample)
JP2022549380A5 (enExample)
JP2024099770A5 (enExample)
JP7541027B2 (ja) 筋肉発現のためのハイブリッドプロモーター
IL278213B1 (en) A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd)
US20040142416A1 (en) Treatment for phenylketonuria
WO2016100575A1 (en) Gene therapy for juvenile batten disease
JP2022524434A5 (enExample)
JP2021533805A5 (enExample)
JP2022551744A5 (enExample)
WO2020142714A1 (en) Aav expression cassette and aav vectors comprising the same
US20260131029A1 (en) Engineered nucleic acid regulatory elements and methods and uses thereof
JP2025521102A5 (enExample)
RU2020132890A (ru) Композиции и способы лечения макулярной дистрофии
JP2021534766A5 (enExample)
JP2023542131A5 (enExample)
JP2025514489A5 (enExample)
CN113891712A (zh) 用于晚期婴儿神经元蜡样脂褐质沉积症2型的aav载体治疗方法
CN120457199A (zh) 截短的atp7b及其用途
JP2025515030A5 (enExample)
KR102874560B1 (ko) 아데노연관바이러스 변이체
JP2023504201A5 (enExample)